@FierceMedDev: ICYMI: Diagnostic companies homing on on rapid mobile tests to quell Ebola outbreak. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Medtronic discloses new corporate structure upon Covidien deal close. Story | Follow @VarunSaxena2
@EmilyWFierce: Boston Scientific set to face first federal trials over transvaginal mesh products. Reuters article | Follow @EmilyWFierce
> Tech companies continue to venture into med tech, especially the wearable devices arena. Microsoft ($MSFT) launched Microsoft Band, a wrist-worn device with sensors that monitor pulse rate, calories burned and sleep quality. Story
> On Friday, shares in spinal implant device company NuVasive reached a 52-week high, as the company reported a loss of $1.8 million on sales of $189.9 million, $10 million higher than expected. News
> Sorin Group, a cardiovascular diseases device company, enrolled 1,039 patients with severe heart failure in a study testing the safety of the SonR cardiac resynchronization therapy (CRT) optimization system, which features a unique hemodynamic sensor. Release
Biotech News
@FierceBiotech: Nymox blasted as lead drug flops in twin PhIII enlarged prostate studies. News | Follow @FierceBiotech
@JohnCFierce: Bristol-Myers beefs up fibrosis pipeline with $444M option deal. Report | Follow @JohnCFierce
@DamianFierce: $BMY gets into IPF with Galecto (and Magnus Persson, its fantastically named chairman) in a deal worth up to $444M. Release | Follow @DamianFierce
@EmilyMFierce: The planet's deadliest infectious diseases, by country. More via Salon | Follow @EmilyMFierce
> Geron shares rocket up after FDA takes the cuffs off its lead drug. Story
> $6B Covance buyout puts LabCorp in the CRO biz. Report
> Takeda drops a $750M schizophrenia drug pact with Intra-Cellular. Item
Pharma News
@FiercePharma: Tops this weekend: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts. Article | Follow @FiercePharma
@EricPFierce: The revamp continues at Takeda, as does its financial struggles. Article | Follow @EricPFierce
@CarlyHFierce: ICYMI: Express Scripts ready to favor AbbVie hep C prospect--provided it undercuts Gilead. Story | Follow @CarlyHFierce
> Bristol-Myers' 91-country hep C access plan still draws fire from price critics. More
> AstraZeneca seals the deal for Almirall's respiratory meds. Article
CRO News
> PRA raises the stakes, eyeing $400M in a blockbuster IPO. More
> CRO Paragon raises $13M to expand its footprint. Story
> LabCorp is buying Covance for $5.6B to cut in on the CRO boom. News
> Timely deals boost Charles River's balance sheet. Story
> Quintiles posts another $1B quarter and dials up its expectations. Report
Biotech IT News
> Venter makes new hires at Synthetic Genomics and Human Longevity. Item
> Cleveland Clinic teams with IBM to use Watson in genomics cancer research. Report
> Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs. More
> Novo Nordisk pushes back date of IT IPO decision to 2015. Story
> Boehringer picks IDBS system in consolidation of ELN. Article
Animal Health News
> IDEXX follows positive earnings with acquisition of Animana. Item
> Advaxis sees encouraging results for immuno-oncology treatment in dogs with bone cancer. Report
> Analysts to Heska: Why has strong performance been overlooked? Article
> Jaguar Animal Health trims IPO target number by 26%. More
> Possible threat to strong launch of Merial's anti-flea pill NexGard adds to Sanofi's woes. Story